LLY spotlight — 2026-10-16
Recent coverage of Eli Lilly (LLY) skews heavily positive, with 11 positive reports and zero negative. This sentiment aligns with a strong upward trend in price action. On Thursday, the stock closed at $1251.61, an increase of 3.55% on…
Key figures
Data as of Oct 16, 2026- LLY last close
- $1,251.61
- LLY change vs prior close
- 3.55%
- LLY market cap
- $1.12T
Recent coverage of Eli Lilly (LLY) skews heavily positive, with 11 positive reports and zero negative¹. This sentiment aligns with a strong upward trend in price action. On Thursday, the stock closed at $1251.61², an increase of 3.55%³ on 3.76 million shares⁴.
The stock is currently trading at 91.9% of its 52-week range⁵, sitting between its low of $783.85 and high of $1292.65⁶˒⁷. This proximity to the yearly high is supported by significant gains across multiple timeframes: 7.01% over the last five sessions⁸, 10.0% over the last month⁹, and 54.07% over the last year¹⁰. LLY currently sits 6.15% above its 50-day average and 15.99% above its 200-day average¹¹.
With a market cap of $1.12T¹², the company last reported revenue of $22.97B¹³ and an EPS of 7.94¹⁴. Trading volume on Thursday was 1.62x the 20-session average¹⁵.
Eli Lilly & Co. (LLY): price and news
Full chart and figuresDaily closes up to Oct 15, 2026, the last session before this was written.
News
- Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.The Motley Fool3d agoPositive
Company dominates the GLP-1 weight loss drug market with blockbuster products (Mounjaro, Zepbound) driving 48% revenue growth in recent quarters. Expected $87 billion revenue in 2026 with analyst estimates exceeding $100 billion for following year. Strong pipeline with promising late-stage candidates (EloraTZP, retatrutide) positions company for sustained growth. Trading at 32x forward earnings below historical levels despite significant stock appreciation, suggesting undervaluation.
- Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.The Motley Fool4d agoPositive
Despite the recent 8% pullback, the article emphasizes Lilly's strong fundamentals including 41% 12-month gains, overwhelming demand for GLP-1 drugs, historical pattern of rebounding from similar declines, and overwhelmingly bullish Wall Street consensus (20 of 23 analysts rating as 'buy' or better) with 16% upside potential. The pullback is characterized as temporary profit-taking rather than a fundamental problem.
- Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026?The Motley FoolOct 6Positive
Demonstrates exceptional growth with 44.7% revenue increase to $65.2 billion in FY2025, operating margins surged to 49.7%, and strong free cash flow of $9.0 billion. Leading position in GLP-1 market with diverse portfolio and next-generation oral pill strategy.
- Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its StockThe Motley FoolOct 5Negative
Stock has elevated valuation at 40x trailing earnings with limited upside potential. High expectations are baked into the price, and intensifying competition in the GLP-1 market could slow growth rates, leading to potential share price decline. Author explicitly recommends against investing at current levels.
- Also mentions this stock
- Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsightPress releaseGlobeNewswire Inc.22h agoPositive
Leading obesity drug developer with multiple Phase III trials showing positive results for retatrutide (triple agonist) and approved oral formulation (orforglipron). Strong pipeline positioning in high-growth obesity market.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Educational tool. Not investment advice. This article was produced with automated assistance. Every figure in it was checked against the underlying data before it was published; the interpretation was not.